Your browser is no longer supported. Please, upgrade your browser.
Settings
PLX Protalix BioTherapeutics, Inc. daily Stock Chart
PLX [NYSE]
Protalix BioTherapeutics, Inc.
Index- P/E- EPS (ttm)-0.74 Insider Own13.90% Shs Outstand126.50M Perf Week-5.19%
Market Cap92.34M Forward P/E- EPS next Y-0.11 Insider Trans0.29% Shs Float116.17M Perf Month-12.05%
Income- PEG- EPS next Q-0.04 Inst Own31.30% Short Float6.39% Perf Quarter-26.63%
Sales11.41M P/S8.09 EPS this Y48.80% Inst Trans-82.30% Short Ratio8.58 Perf Half Y26.96%
Book/sh-0.55 P/B- EPS next Y50.00% ROA- Target Price3.40 Perf Year13.34%
Cash/sh- P/C- EPS next 5Y25.00% ROE- 52W Range0.26 - 1.51 Perf YTD64.04%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-51.80% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low180.77% ATR0.04
Employees232 Current Ratio- Sales Q/Q325.50% Oper. Margin- RSI (14)36.39 Volatility7.05% 5.35%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.27 Prev Close0.78
ShortableYes LT Debt/Eq- EarningsAug 07 BMO Payout- Avg Volume864.59K Price0.73
Recom1.50 SMA20-7.80% SMA50-12.10% SMA200-4.76% Volume1,094,801 Change-6.41%
Apr-17-17Reiterated Rodman & Renshaw Buy $4 → $5
Apr-04-16Initiated Rodman & Renshaw Buy $3.50
Apr-23-15Upgrade Jefferies Hold → Buy $2 → $2.60
Nov-12-14Reiterated R. F. Lafferty Buy $8 → $5
Jan-24-14Initiated R. F. Lafferty Buy $8
May-02-12Reiterated Oppenheimer Outperform $9 → $11
May-02-12Downgrade Canaccord Genuity Buy → Hold $8 → $8
Apr-30-12Downgrade Auriga Buy → Hold $8 → $8
Oct-13-11Initiated Morgan Joseph Hold
Mar-17-11Downgrade WBB Securities Strong Buy → Buy $10
Nov-09-10Reiterated Oppenheimer Outperform $10 → $12
Oct-14-10Reiterated UBS Buy $9 → $10.75
Dec-02-09Reiterated Hapoalim Outperform $10 → $12
Sep-22-09Initiated Canaccord Adams Buy
Sep-02-09Initiated Hapoalim Outperform $10
Dec-01-08Reiterated Oppenheimer Outperform $6 → $4
Mar-11-08Initiated UBS Buy $6
Nov-20-07Initiated CIBC Wrld Mkts Sector Outperform $7
Jul-25-17 04:28PM  Protalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 for $8.55 million Notes Maturing February 2022 GlobeNewswire
Jun-07-17 07:30AM  Protalix BioTherapeutics Announces Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis Presented at the 40th European Cystic Fibrosis Society Conference GlobeNewswire -5.79%
Jun-01-17 07:30AM  Protalix BioTherapeutics Announces FDA Approval to Operate its Current Facility as a Multi-Product Facility GlobeNewswire
May-30-17 08:50AM  Are Options Traders Betting on a Big Move in Protalix BioTherapeutics (PLX) Stock? Zacks
May-25-17 07:30AM  Protalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-23-17 07:30AM  Protalix BioTherapeutics Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference GlobeNewswire +10.71%
May-12-17 11:37AM  Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube
May-11-17 07:30AM  Edited Transcript of PLX earnings conference call or presentation 10-May-17 12:30pm GMT Thomson Reuters StreetEvents
May-10-17 07:40AM  Protalix reports 1Q loss Associated Press
07:30AM  Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update GlobeNewswire
May-09-17 07:30AM  Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease GlobeNewswire
May-01-17 07:50AM  Protalix BioTherapeutics to Hold First Quarter 2017 Financial Results and Corporate Update Conference Call on May 10, 2017 GlobeNewswire
Apr-18-17 07:30AM  Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies GlobeNewswire
Apr-13-17 07:30AM  Apricus Biosciences and Protalix Biotherapeutics Seeing Opposite Sides of FDA Clinical Trials Accesswire -5.41%
Apr-12-17 09:20AM  Protalix Cystic Fibrosis Drug Study Results Worsen Over Time TheStreet.com -15.27%
07:30AM  Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of alidornase alfa (AIR DNase) for the Treatment of Cystic Fibrosis GlobeNewswire
Apr-04-17 09:00AM  Do Options Traders Know Something About Protalix (PLX) Stock We Don't? Zacks
08:15AM  Blog Coverage Kitov Received a $2 Million Filing Waiver from FDA Accesswire
08:15AM  Blog Coverage Kitov Received a $2 Million Filing Waiver from FDA
Mar-23-17 01:04PM  PROTALIX BIOTHERAPEUTICS, INC. Financials
Mar-20-17 09:03AM  Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube -5.74%
09:03AM  Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
Mar-16-17 08:09AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition -6.25%
08:00AM  Protalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporate Update GlobeNewswire
07:07AM  Q4 2016 Protalix Biotherapeutics Inc Earnings Release - Time Not Supplied
Mar-14-17 09:30AM  Cerulean Pharma Attracts Investors and Possible Suitor, Protalix Returns to the Spotlight Accesswire
Mar-13-17 09:30AM  Today's Research Report on Trending Biotech Tickers: Protalix Biotherapeutics and Stemline Therapeutics Accesswire +21.19%
Mar-09-17 07:30AM  Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017 GlobeNewswire
Feb-17-17 07:44AM  Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta TheStreet.com -6.90%
07:44AM  Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
Feb-16-17 04:32PM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure -7.20%
Feb-14-17 06:11PM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Shareholder Director Nominations
04:12PM  Protalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders GlobeNewswire
Feb-13-17 07:00AM  Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium 2017 GlobeNewswire +29.70%
Feb-03-17 09:45AM  M&A Activity Could Kick Start Biotech Industry's Recovery in 2017: Today's Report on Benitec and Protalix Accesswire
Jan-30-17 08:00AM  Protalix BioTherapeutics (PLX) Jumps: Stock Rises by 11.7%
Jan-09-17 06:13AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Discl
06:00AM  Protalix BioTherapeutics Provides Review of 2016 and Strategic Outlook for 2017 GlobeNewswire
Jan-03-17 07:40AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events -6.67%
07:30AM  Protalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of alidornase alfa (AIR DNase) for the Treatment of Cystic Fibrosis GlobeNewswire
Dec-30-16 11:32AM  Protalix Biotherapeutics Inc (PLX) Could Run Up On Interim CF Data at Insider Monkey
07:45AM  7 Key FDA Decisions and Catalysts Expected in January and February at 24/7 Wall St.
Dec-27-16 07:39AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events +12.03%
07:30AM  Protalix BioTherapeutics Receives Confirmation of Order for over $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil GlobeNewswire
Dec-26-16 10:42AM  Protalix Biotherapeutics Inc. (PLX) Attracts A Huge Investment By A Large Hedge Fund at Insider Monkey
Dec-22-16 07:30AM  Protalix BioTherapeutics Announces Last Patient Enrolled in the AIR DNase Phase II Clinical Trial for Cystic Fibrosis GlobeNewswire +11.50%
Dec-15-16 08:15AM  Blog Coverage Protalix Receives Letter Intending Purchase of Alfataliglicerase to Treat Gaucher Patients in Brazil Accesswire -11.07%
Dec-14-16 07:40AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events +11.67%
07:30AM  Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil GlobeNewswire
Dec-13-16 04:04PM  Alexion, Ophthotech Dont Escape Tuesdays 52-Week Low Club -7.98%
Dec-07-16 05:28PM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct F -9.09%
Dec-05-16 04:04PM  FitBit, Teva Slide into Mondays 52-Week Low Club at 24/7 Wall St.
Dec-02-16 04:04PM  Coty, Fitbit Fall into Fridays 52-Week Low Club at 24/7 Wall St. -44.59%
06:04AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and E
Dec-01-16 05:00PM  Protalix BioTherapeutics Announces Investor Call GlobeNewswire
04:44PM  Protalix BioTherapeutics Announces Private Note Exchanges and Private Placement of Secured Convertible Notes due 2021 GlobeNewswire
Nov-30-16 08:25AM  Protalix BioTherapeutics (PLX) Jumps: Stock Rises 14.3%
08:02AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events
07:30AM  Protalix BioTherapeutics Enrolls First Patient in Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis GlobeNewswire
Nov-22-16 04:20PM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events +7.28%
09:25AM  Alfataliglicerase Approved for Pediatric Indications in Brazil for the Treatment of Gaucher Disease in Children Four years and Older GlobeNewswire
Nov-10-16 11:29AM  Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016
Nov-09-16 08:36AM  Protalix reports 3Q loss +7.32%
08:10AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
08:00AM  Protalix BioTherapeutics Provides Update and Reports 2016 Third Quarter Results GlobeNewswire
Oct-25-16 07:42AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events
07:30AM  Protalix BioTherapeutics Doses First Patient in Global Phase III Clinical Trial of PRX-102 for the Treatment of Fabry Disease GlobeNewswire
Sep-07-16 07:00AM  Protalix BioTherapeutics Announces Presentation of Results from the Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease at the Society for the Study of Inborn Errors of Metabolism GlobeNewswire
Aug-10-16 07:40AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events
07:30AM  Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease GlobeNewswire
Aug-08-16 07:33PM  Protalix reports 2Q loss
04:41PM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:30PM  Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results GlobeNewswire
Jul-07-16 07:37AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events
07:30AM  Protalix BioTherapeutics Announces First Patient Dosed in the AIR DNase Phase II Clinical Trial for Cystic Fibrosis GlobeNewswire
Jul-04-16 07:01PM  Point Loma Resources Ltd. Will Open for Trading July 5, 2016 on TSXV Marketwired
04:35PM  IIROC Trading Resumption - PLX PR Newswire
Jun-07-16 09:35AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jun-06-16 07:09AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events
07:00AM  Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial of Fabry Disease to Support United States and European Filings GlobeNewswire
Jun-02-16 07:30AM  Protalix BioTherapeutics to Present at the Jefferies 2016 Global Healthcare Conference GlobeNewswire
May-19-16 02:54AM  Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2016 By the Numbers : May 19, 2016
May-17-16 01:20PM  Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2016 By the Numbers
May-09-16 07:59AM  Protalix reports 1Q loss
07:17AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
07:00AM  Protalix BioTherapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
Apr-08-16 05:01PM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events
Apr-04-16 07:06AM  Coverage initiated on Protalix BioTherapeutics by Rodman & Renshaw
Apr-01-16 05:02PM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, F
Mar-08-16 07:38AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
07:33AM  Protalix BioTherapeutics Reports Fiscal Year 2015 Financial Results and Provides Corporate Update GlobeNewswire
Mar-03-16 07:07AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events +5.83%
07:00AM  Protalix BioTherapeutics Presents Positive Six and Twelve Month Interim Clinical Data on PRX-102 for the Treatment of Fabry Disease at the 12th Annual WORLDSymposium 2016 GlobeNewswire
Feb-22-16 07:30AM  Protalix BioTherapeutics to Participate in the SunTrust Robinson Humphrey Orphan Drug Day and the 12th Annual WORLDSymposium 2016 GlobeNewswire
Jan-04-16 04:31PM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Shareholder Director Nominations
Dec-22-15 09:49AM  Protalix Biotherapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Nov-28-15 03:23AM  Is Protalix BioTherapeutics Inc. (PLX) A Good Stock To Buy? at Insider Monkey
Nov-23-15 04:07PM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Nov-17-15 04:45PM  Protalix Meets FDA, To Start Phase III Fabry Disease Study
Nov-16-15 07:16AM  PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Manor MoshePresident & CEOMay 16Buy0.8150,00040,50050,000May 16 09:31 AM
Camber Capital Management LLC10% OwnerDec 02Sale0.322,500,000792,00010,775,000Dec 06 03:26 PM
Shaaltiel YosephExecutive VP, R&DSep 15Option Exercise0.00122,162122585,916Sep 16 05:01 PM